Please enable JavaScript.
Coggle requires JavaScript to display documents.
DNA Vaccines - The Outer Frontier 🧬 - Coggle Diagram
DNA Vaccines - The Outer Frontier 🧬
What Are DNA Vaccines?
A. Core Concept
Uses the GENETIC MATERIAL (DNA) of the virus/bacteria.
NO Live Attenuated or Killed Pathogens.
B. How They Are Made
Isolate a gene from the target pathogen.
Splice the gene into a DNA Vector (Bacterial Plasmid - a circular genetic structure).
Replicate & Purify the plasmid in the lab.
Delivery Methods
"Gene Gun": Plasmid layered on gold beads, shot directly into tissue with high-pressure gas.
Future Goal: Liquid form as a Nasal Spray.
Injection (Standard).
Advantages Over Established Methods
Safety Profile
Considered MUCH SAFER than Live Attenuated vaccines.
Reason: Plasmids are NON-LIVING and NON-REPLICATING.
NO RISK of mutating back to the virulent form and causing illness.
Versatility & Cost
Therapeutic (Fighting existing disease, e.g., CANCER).
Cost-Effective (Well-tolerated and inexpensive to produce).
Prophylactic (Preventative, e.g., targeting a pathogen).
Immune Response
Result: Long-lasting immunity (Similar to Live Attenuated).
Elicits a STRONG DUAL RESPONSE
Cellular Response: Activates "Killer" Cytotoxic T cells and Helper T cells.
Humoral Response: Triggers B cells to produce Antibodies.
Challenges & Limitations
Main Effectiveness Concern
Low Level of Immunogenicity (Simply NOT EFFECTIVE ENOUGH yet).
Other Concerns
Ability to Disrupt Cellular Processes.
Potential to produce Anti-DNA Antibodies.
Current Status
Human trials have shown MIXED RESULTS.
Vast majority are STILL IN CLINICAL TRIALS.
Future Outlook & Market Growth
Driving Forces
Advancements in Biotechnologies and Nanotechnologies are key to improving efficacy.
Continued breakthroughs are highly anticipated.
The Ultimate Goal
Hope for eradicating currently incurable illnesses in the near future.
Potential to inoculate against devastating maladies: Malaria, HIV, and Cancer.
Market Trajectory
Global market has grown tremendously.
Example: Valued at $244M (2013) → Expected to hit $2.7B (2019).